NCT02313532 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bergus GR, Levy BT, Levy SM, Slager SL, Kiritsy MC
Antibiotic use during the first 200 days of life. Arch Fam Med. 1996 Oct;5(9):523-6.
Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A
Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. Pediatr Infect Dis J. 1998 Oct;17(10):880-5.
Ladhani S, Gransden W
Increasing antibiotic resistance among urinary tract isolates. Arch Dis Child. 2003 May;88(5):444-5.
Scheifele D, Halperin S, Pelletier L, Talbot J
Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis. 2000 Jul;31(1):58-64. Epub 2000 Jul 24. Erratum in: Clin Infect Dis 2000 Sep;31(3):850.
Seppälä H, Nissinen A, Järvinen H, Huovinen S, Henriksson T, Herva E, Holm SE, Jahkola M, Katila ML, Klaukka T, et al
Resistance to erythromycin in group A streptococci. N Engl J Med. 1992 Jan 30;326(5):292-7.
Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000 Dec 28;343(26):1917-24.

Treatment of Febrile Infectious Disease Among Children in Hadera District Given the Final Diagnosis. Descriptive Study

Clinical trial NCT02313532 - References